AN2 Therapeutics (ANTX) Non-Current Assets (2021 - 2025)

AN2 Therapeutics (ANTX) has 5 years of Non-Current Assets data on file, last reported at $2.0 million in Q4 2025.

• Non-Current Assets for Q4 2025 came in at $2.0 million, down 65.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (down 27.44% YoY), and the FY2025 annual result was $2.0 million, down 65.44% from the prior year.
• Non-Current Assets declined to $2.0 million in Q4 2025 per ANTX's latest filing, from $3.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $28.2 million in Q4 2023 and troughed at $720000.0 in Q1 2022.
• A 5-year average of $6.9 million and a median of $3.6 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 910.29% in 2023, then sank 79.37% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $5.2 million in 2021, then declined by 24.4% to $3.9 million in 2022, then surged by 616.86% to $28.2 million in 2023, then slumped by 79.37% to $5.8 million in 2024, then slumped by 65.44% to $2.0 million in 2025.
• Business Quant data shows ANTX's Non-Current Assets at $2.0 million in Q4 2025, $3.2 million in Q3 2025, and $8.3 million in Q2 2025.